To the people who claimed here to dump and buy CLSN. Oh my what a mistake!
Typical bad risk/reward call. EXEL has an already approved product, and all they have to do for that one is show efficacy, and they will get greatly expanded use. With CLSN you had basically the one shot pony that crashed on failure. Some still do not get it. EXEL has many partners and deals, with an approved product that looks to have wide ranging applications. Risk far less. Reward far greater. Smart money would have sold CLSN and bought EXEL . Not the other way around. Better upside here, less risk, and more potential in multiple products.